STAT+: Pharmalittle: We’re reading about Trump and drug prices, biotechs pushing back, and more

Reining in drug prices has been a significant focus for both the Trump and Biden administrations. However, recent polls indicate that former President Donald Trump is receiving more credit for his efforts to lower drug prices compared to President Joe Biden. This perception may be influenced by Trump's initiatives, such as TrumpRx, which have drawn considerable attention. The emphasis on drug pricing reform has been a bipartisan issue, with both administrations recognizing the need to address the high costs of medications. Despite this shared priority, the narrative surrounding the effectiveness and recognition of each administration's efforts appears to favor Trump. Polling data suggests that the public associates Trump's actions more closely with positive outcomes in drug pricing than those of Biden. As the debate over drug prices continues, the contrasting perceptions of the two administrations highlight the complexities of public opinion regarding healthcare policies. Trump's approach and the initiatives he championed seem to resonate more with certain segments of the population, leading to a greater acknowledgment of his contributions in this area. This dynamic could influence future discussions and policies related to drug pricing and healthcare reform.